All stock reports

RELAXO evidence report

Evidence date: 2026-10-01. Research observations only.

What can I do with this stock?

Evaluated 2026-10-02T01:37:53.224812+00:00. Closed-session evidence: 2026-10-01. This is a timestamped assessment, not a live trading feed.

Strategy evidence, instrument feasibility and portfolio suitability are separate. Portfolio suitability has not been assessed.

Today: intraday

Evidence unavailable

No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

  • No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

Next week: five trading sessions

No qualifying opportunity

No candidate with a primary five-session horizon in the coherent source run.

  • No candidate with a primary five-session horizon in the coherent source run.

Long term: one to three years

Research only

A financial screen alone does not establish an investment recommendation.

  • A current, source-backed thesis and valuation review is required.

Investment evidence

Statement coverage
FULL_STATEMENTS
Financial source retrieved
2026-09-29T00:55:55.981284+00:00

Metrics

latest_annual_period
2026-03-31
revenue
27021600000.0
net_income
1792700000.0
operating_cash_flow
3604400000.0
free_cash_flow
2239700000.0
total_assets
29489400000.0
total_liabilities
7425800000.0
total_equity
22063600000.0
cash
241900000.0
total_debt
2326500000.0
revenue_growth
-0.03134846806542846
earnings_growth
0.052486350026419215
net_margin
0.06634322171892115
roe
0.08125147301437662
debt_to_equity
0.1054451676063743
cash_conversion
2.0105985385173204
free_cash_flow_margin
0.08288554341711815
trailing_pe
131.06
forward_pe
Not supplied
peg_ratio
Not supplied
price_to_book
Not supplied
dividend_yield
Not supplied

Other positional research

Research only

1 opportunity assessments; compare evidence and conditions below.

Price Dislocation

Research only. Direction: LONG.

Flags large price dislocations for research without asserting unsupported fundamental quality

  • No active, unexpired validation authority for this exact strategy and horizon.
  • A source-backed entry, invalidation, exit and cost plan is not supplied.
Eligible expression
None selected
Expression comparison
No eligible instrument selected.
Invalidation
Continued price deterioration or adverse fundamental evidence
Entry rule
Not supplied
Entry range (INR)
Not supplied
Exit / review rule
Not supplied
Planned exit
Not supplied
Plan valid until
Not supplied
Promotion reference
Not supplied
Instrument scenarios in INR; quantities are illustrative, not personal sizing
InstrumentEvidence statusContractQuantityCapital / marginTarget P&L after costsStop-level scenario P&LStress lossConditions and limitations
NO_POSITIONAvailableNot suppliedNot suppliedNot supplied0.000.00Not suppliedNo new position; incremental trading P&L is zero.
CASHUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
FUTURESUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
OPTIONSUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
  • No reader capital or loss budget supplied
Decision provenance and limitations
Decision ID
decision-a708373552748a5488711120b87549de2612a9d18a598741d062150f56d19023
Policy
stock-decisions-v1
Evidence bundle hash
b3eca6197b632c5278474433bfa00fa8b8e1a3b12940e9b4c855bd2f56be939b
  • market-brief: a7de4d64fedac164d48cdfb9b4081a4666d7f797f7d9c58da304b329b3a61d3c
  • validation-registry: b1069587129bfc64a703cdf8322d0294692585b7d67f5472593e4164bbb0c3bc
  • financial-statements: 5cb493a7f82e160b946d3c0218f6427cd0ad39a3c58c1410e8369a9b4a474a9e
  • daily-price: 28dc4e83777ea2553577d4d7b27900ba05dea859267439afafbbc99cbe358c4e
  • Conditional research decisions are not orders or personalized position sizes.
  • Scenario payoffs are assumptions, not probabilities or expected returns.
  • A stop price does not guarantee a maximum loss through a gap or illiquidity.

Download the decision evidence as JSON

Numerical report available. Evidence briefing is queued or awaiting retry.

Cached observations and evidence limits